Showing posts with label victims. Show all posts
Showing posts with label victims. Show all posts

Monday, August 29, 2011

Origin of Connective Tissue Type Mesotheliomas from Multipotential Spindle Cells



Another interesting study entitled "Pleural mesothelioma of connective tissue type, localized fibrous tumor of the pleura, and reactive hyperplasia submesothelial immunohistochemical comparison." Moutaiz by Al-Izzi, Nicola P. Thurlow, Professor Bryan Corrin -. Journal of Pathology, Volume 158, Issue 1, pages 41-44, May 1989 Here is an excerpt: "Abstract - Ten diffuse pleural mesotheliomas connective tissue type were compared with 14 examples of pleural granulation tissue and 7 localized fibrous tumors of the pleura, using immunohistochemistry to identify cytokeralins oflow and high molecular weight and vimentin. low-molecular-weight cytokeratin and vimentin are both delected in 8 of 10 mesotheliomas and 12 of 14 reactive iesions. cylokeratin high molecular weight is rarely detected or lesions. seven of localized fibrous tumors of the pleura are all positive and negative for virnentin for cytokeratins. These results support the origin of connective tissue type mesotheliomas multipotential submesothelial spindle cells and localized fibrous tumors of the pleura from any conventional fibroblasts or resting submesothelial stem cells. cytokeratin antibodies to help distinguish these two neoplasms, but does not provide help in difficult diagnostic problem of distinguishing mesotheliomas of the connective tissue type of pleural reaction is characterized by abundant granulation tissue ."

Another interesting study titled, "Final analysis of multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine / cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts ) with malignant mesothelioma (MM) "-

Another interesting study titled, "Final analysis of multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine / cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts ) with malignant mesothelioma (MM) "-














Sunday, August 21, 2011

Mesothelioma Research Limitations and Computed Tomography



Another interesting study titled "Impact of drug light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma" Hans-Beat Ris, Hans Jörg Altermatt, Bernhard Nachbur, J. Charles M. Stewart, Qiang. Wang, Chang Kee Lim, Raymond Bonnett, Ulrich Althaus - International Journal of Cancer Volume 53, Number 1, p. 141-146, 2 January 1993 Here is an excerpt: "Summary - The influence of time interval (TI) between the drug and laser activation on the selectivity meta-tetrahydroxy-phenylchlorin (mTHPC)-mediated photodynamic therapy (PDT) for tumor tissue was evaluated in BALB / c nude mice bearing human malignant mesothelioma xenografts. the following IP administration of 0.3 mg / kg mTHPC, light dose of 10 J / cm2 and 0.1 W/cm2 was delivered at 650 nm in the tumor and the same size area of ​​the hind legs after the fourth I2, 24 and 36 hours, and 2.3, 4.5 and 6 days in groups of 6 animals (surface radiation ). Then, 72 hours after the delivery of light, depth of necrosis was measured in the tumor and the skin and underlying muscle hind legs. Photosensitized necrosis occurred in the normal tissue of the TI with 4 hr 3 days and tumor TI with I2 to 4 GB days. therapeutic ratio of mTHPC-PDT significantly varied with the time interval between the drug and the laser activated, and was the largest in the span of three days. mTHPC concentrations measured in 3 control unirradiated animals at all time points in normal tissues and tumor tissues, and it was found that same in both tissues. the tissue concentration of mTHPC was limited use in relation to the prediction of photosen-sitizing effects in tumor model ."

Another interesting study titled "Impact of drug light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma" Hans-Beat Ris, Hans Jörg Altermatt, Bernhard Nachbur, J. Charles M. Stewart, Qiang. Wang, Chang Kee Lim, Raymond Bonnett, Ulrich Althaus - International Journal of Cancer Volume 53, Number 1, p. 141-146, 2 January 1993 Here is an excerpt: "Summary - The influence of time interval (TI) between the drug and laser activation on the selectivity meta-tetrahydroxy-phenylchlorin (mTHPC)-mediated photodynamic therapy (PDT) for tumor tissue was evaluated in BALB / c nude mice bearing human malignant mesothelioma xenografts. the following IP administration of 0.3 mg / kg mTHPC, light dose of 10 J / cm2 and 0.1 W/cm2 was delivered at 650 nm in the tumor and the same size area of ​​the hind legs after the fourth I2, 24 and 36 hours, and 2.3, 4.5 and 6 days in groups of 6 animals (surface radiation ). Then, 72 hours after the delivery of light, depth of necrosis was measured in the tumor and the skin and underlying muscle hind legs. Photosensitized necrosis occurred in the normal tissue of the TI with 4 hr 3 days and tumor TI with I2 to 4 GB days. therapeutic ratio of mTHPC-PDT significantly varied with the time interval between the drug and the laser activated, and was the largest in the span of three days. mTHPC concentrations measured in 3 control unirradiated animals at all time points in normal tissues and tumor tissues, and it was found that same in both tissues. the tissue concentration of mTHPC was limited use in relation to the prediction of photosen-sitizing effects in tumor model ."

Another interesting study titled "Malignant mesothelioma of the pleura:. Clinical aspects and symptomatic treatment," Law MR, Hodson ME, Turner-Warwick M. Here is an excerpt: "Abstract - series of 140 patients with malignant pleural mesothelioma reported clinical presentation was postponed in the case without large effusion, but the tumor is extensive. the presentation, they showed thoracoscopy, thoracotomy, or computed tomography in all patients investigated. thoracoscopy was a useful diagnostic alternative to thoracotomy. with disease progression, mesothelial expansion was more important than distant metastases, which are usually too small and they rarely produce symptoms. skin tumor deposits in areas of previous invasive procedures are not causing pain or other clinical problems, and we believe that diagnostic and therapeutic procedures should not be withheld to avoid them. in the management recurrent pleural effusion, intrapleural bleomycin, preceded by desire, and after vacuuming, a useful alternative to surgery, pneumothorax, spontaneous or iatrogenic, it decortication Adequate pain relief is difficult .. radiation therapy and nerve block procedures were not effective and the drugs are often necessary. "

We all owe debt of gratitude to these fine researchers. If you find any of these statements interesting, please read the study in its entirety.

Sunday, August 14, 2011

Mesothelioma and Pulmonary Decortication



Another interesting study titled "Pleurectomy for mesothelioma." Do Brancatisano RP, Joseph MG, McCaughan BC - Department of Surgery, Repatriation General Hospital Concord, NSW Med J Aust .. . 1st April 1991; 154 (7) :455-7, 460 Here is an excerpt: "Abstract - Objective: To evaluate the efficacy and safety of parietal pleurectomy in establishing a tissue diagnosis and control of pleural fluid accumulation in patients with pleural mesothelioma, and assess the success of this procedure caused mitigation DESIGN aND SETTING:. fifty consecutive patients with pleural mesothelioma who underwent thoracotomy for cardiac units in Concord and Royal Prince Alfred Hospital were reviewed retrospectively male:. female ratio was 04:01 and mean age was 63 years in only 11 of 50 patients had tissue diagnosis of mesothelioma was before the surgery INTERVENTIONS: .. the thoracotomy, subtotal parietal pleurectomy was performed in 45 of 50 patients in two patients. biopsy only was performed, and three patients were treated by chemical pleurodesis only as pleurectomy is not technically possible . pulmonary decortication was required in 28 patients to allow full expansion of the underlying lung for effective pleurodesis.

RESULTS: There was one postoperative smrt.Morbiditeta was 16%. Without a patient who died in the postoperative period, median survival was 16 months, ranging from three to 54 months, with 21% of patients surviving for more than two years. Only one patient developed a reaccumulation of pleural fluid.

Conclusion: Pleurectomy with decortication if necessary, and provide tissue diagnosis and effective control of pleural fluid accumulation and thus a great reduction in patients with pleural mesothelioma. We advocate early thoracotomy in these patients ."














Monday, August 8, 2011

Adenoviral Gene Transfer and Mesothelioma Cancer Cell Lines



Another interesting study called "adenovirus-mediated Bak gene transfer causes apoptosis in mesothelioma cell lines" by Abujiang Pataer, MD, PhD, W. Roy Smythe, Dr. Robert Yu, MS, Bingliang Fang, MD, PhD . sc, Tim McDonnell, MD, PhD, Jack A. Roth, Dr. Stephen G. Swisher, MD - from the Department of Thoracic Molecular Oncology, Department of Thoracic and cardiovascular surgery, and Institute of Molecular Pathology, University of Texas MD. Anderson Cancer Center, Houston, Texas - General Thoracic Surgery, J Thorac Cardiovasc Surg 2001; 121:0061-0067 Here is an excerpt: "Objective: Conventional treatment for mesothelioma is largely ineffective, therefore, evaluated the new approach. By adenoviral gene transfer of proapoptotic Bcl-2 family Bak in mesothelioma cancer cell lines, which are sensitive and resistant to adenoviral p53.

Methods: Binary adenoviral Bak (Ad / GT-Bak and Ad/GV16) and Laczi (Ad / GT-Laczi and Ad/GV16) vectors were used to convert from mesothelioma cell lines I-45 (p53-resistant ) and REN (p53-sensitive). Protein levels are determined by Western blotting. Apoptosis was assessed morphological changes, caspase-3 cleavage, and fluorescence-activated cell sorting analysis of subdiploid populations. Cell viability was determined by XTT assay. Statistical analysis was performed with analysis of variance and Student test.

Methods: Binary adenoviral Bak (Ad / GT-Bak and Ad/GV16) and Laczi (Ad / GT-Laczi and Ad/GV16) vectors were used to convert from mesothelioma cell lines I-45 (p53-resistant ) and REN (p53-sensitive). Protein levels are determined by Western blotting. Apoptosis was assessed morphological changes, caspase-3 cleavage, and fluorescence-activated cell sorting analysis of subdiploid populations. Cell viability was determined by XTT assay. Statistical analysis was performed with analysis of variance and Student test.

...

Methods: Binary adenoviral Bak (Ad / GT-Bak and Ad/GV16) and Laczi (Ad / GT-Laczi and Ad/GV16) vectors were used to convert from mesothelioma cell lines I-45 (p53-resistant ) and REN (p53-sensitive). Protein levels are determined by Western blotting. Apoptosis was assessed morphological changes, caspase-3 cleavage, and fluorescence-activated cell sorting analysis of subdiploid populations. Cell viability was determined by XTT assay. Statistical analysis was performed with analysis of variance and Student test.

...

Methods: Binary adenoviral Bak (Ad / GT-Bak and Ad/GV16) and Laczi (Ad / GT-Laczi and Ad/GV16) vectors were used to convert from mesothelioma cell lines I-45 (p53-resistant ) and REN (p53-sensitive). Protein levels are determined by Western blotting. Apoptosis was assessed morphological changes, caspase-3 cleavage, and fluorescence-activated cell sorting analysis of subdiploid populations. Cell viability was determined by XTT assay. Statistical analysis was performed with analysis of variance and Student test.

...

Adenoviral Gene Transfer and Mesothelioma Cancer Cell Lines



Another interesting study called "adenovirus-mediated Bak gene transfer causes apoptosis in mesothelioma cell lines" by Abujiang Pataer, MD, PhD, W. Roy Smythe, Dr. Robert Yu, MS, Bingliang Fang, MD, PhD . sc, Tim McDonnell, MD, PhD, Jack A. Roth, Dr. Stephen G. Swisher, MD - from the Department of Thoracic Molecular Oncology, Department of Thoracic and cardiovascular surgery, and Institute of Molecular Pathology, University of Texas MD. Anderson Cancer Center, Houston, Texas - General Thoracic Surgery, J Thorac Cardiovasc Surg 2001; 121:0061-0067 Here is an excerpt: "Objective: Conventional treatment for mesothelioma is largely ineffective, therefore, evaluated the new approach. By adenoviral gene transfer of proapoptotic Bcl-2 family Bak in mesothelioma cancer cell lines, which are sensitive and resistant to adenoviral p53.

Methods: Binary adenoviral Bak (Ad / GT-Bak and Ad/GV16) and Laczi (Ad / GT-Laczi and Ad/GV16) vectors were used to convert from mesothelioma cell lines I-45 (p53-resistant ) and REN (p53-sensitive). Protein levels are determined by Western blotting. Apoptosis was assessed morphological changes, caspase-3 cleavage, and fluorescence-activated cell sorting analysis of subdiploid populations. Cell viability was determined by XTT assay. Statistical analysis was performed with analysis of variance and Student test.

Results: High levels of Bak gene transfer were seen after coadministration Ad / GT-Bak and Ad/GV16 in both mesothelioma cell lines. Apoptosis is induced 24 hours after Bak but not Laczi gene transfer ([Bak: I-45, 36%, Ren, 25%] vs [Laczi: I-45, 1%, Ren, 3%], p <0 , 05]) in p53-sensitive (REN) and p53-resistant (I-45) cell lines. The cell viability was significantly reduced by 48 to 72 hours after Bak gene transfer compared with the control vector in both cell lines (72 hours: Bak I-45, 1.4% ± 1.0%, and Bak REN, 4.7% ± 1%, vs Lac-Z-45, 83% ± 3%, and Lac-Z REN, 100% ± 1%, P <0.05 ).


Conclusion: adenovirus-mediated overexpression of Bak gene causes apoptosis and decreased cell viability in p53-sensitive and p53-resistant mesothelioma cells. These data suggest that gene transfer of proapoptotic Bcl-2 family members may represent a novel strategy for gene therapy for treatment of mesothelioma.

Conclusion: adenovirus-mediated overexpression of Bak gene causes apoptosis and decreased cell viability in p53-sensitive and p53-resistant mesothelioma cells. These data suggest that gene transfer of proapoptotic Bcl-2 family members may represent a novel strategy for gene therapy for treatment of mesothelioma.